Viva Biotech (HKG:1873) expects an attributable profit of between 150 million yuan and 180 million yuan for the year 2024, against an attributable loss of 116.1 million yuan a year prior, a Thursday filing with the Hong Kong bourse said.
The biotechnology firm's adjusted non-IFRS attributable profit will fall between 240 million yuan and 270 million yuan for the year, mainly attributable to a substantial growth recovery of the contract research organization business, higher operating margins, and investment gains.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.